The New AccelStim: Advanced Features, Same Proven Results

Revolutionary LIPUS Technology Now Available with Enhanced Features for Faster Fracture Recovery

We are excited to announce the launch to the new AccelStim™, the latest evolution in our bone healing therapy portfolio. Building on the proven success of our original AccelStim device, which has helped thousands of patients accelerate their fracture healing since its FDA approval in 2022, the new AccelStim represents a significant advancement in Low-Intensity Pulsed Ultrasound (LIPUS) technology.

What Makes the New AccelStim Different?

The new AccelStim incorporates improvements while maintaining the clinically proven LIPUS technology that has made Orthofix the leader in bone growth stimulation. The device continues to deliver 1,000 pulses per second of targeted ultrasound energy to stimulate bone healing at the molecular, cellular, and tissue levels.

Key enhancements include:

• Improved portability with a sleeker, more compact design
• Enhanced battery life for extended treatment sessions without interruption
• Advanced user interface with intuitive controls and progress tracking
• Upgraded comfort features for better patient compliance during the recommended 20-minute daily treatments.

Expanding Treatment Options for Patients

AccelStim is indicated for:

• Non-invasive treatment of established nonunions (excluding skull and vertebra)
• Accelerating healing time for fresh, closed, posteriorly displaced distal radius fractures
• Accelerating healing time for fresh, closed, or Grade I open tibial diaphysis fractures in skeletally mature adults

This broad range of indications, combined with our existing PEMF device portfolio including CervicalStim™, SpinalStim™, and PhysioStim™ systems, positions Orthofix as the only company offering both PEMF and LIPUS bone growth stimulation technologies.

Supporting Patients Through Their Healing Journey

One of the most significant advantages of AccelStim is its non-invasive nature and minimal disruption to daily routines. The device is designed to integrate seamlessly into patients’ lives while providing powerful therapeutic benefits.

Patient benefits include:

• Effective treatment for patients with risk factors, including obesity, diabetes, osteoporosis, and advanced age
• Proven improvement in healing outcomes for smokers, who traditionally face greater challenges with fracture recovery
• Freedom of movement during treatment sessions
• No known contraindications

The treatment protocol remains straightforward: 20 minutes of daily therapy that patients can complete while reading, watching television, or engaging in other sedentary activities.

Leading Innovation in Bone Growth Stimulation

Since 1986, Orthofix Bone Growth Therapy has been at the forefront of promoting natural bone healing processes. With more than a million patients treated using our bone growth stimulation technologies, we understand the critical importance of providing effective, patient-friendly solutions.

AccelStim represents our continued commitment to advancing bone healing therapy through innovation. By combining proven LIPUS technology with enhanced user experience features, we are helping healthcare providers offer their patients the most advanced bone healing solutions available.

Looking Forward

The launch of the new AccelStim device reinforces Orthofix’s position as the market leader in bone growth stimulation devices. With the most comprehensive portfolio of treatment indications in the bone growth stimulation market, we are uniquely positioned to serve the diverse needs of patients and healthcare providers.

As we continue to expand access to these life-changing technologies, AccelStim will play a crucial role in growing the bone growth stimulation market and improving outcomes for patients facing challenging fracture healing scenarios.

For more information about AccelStim or to learn about prescribing options, visit BoneGrowthTherapy.com or contact Patient Care at 800.535.4492.